Roche (SWX: RO, ROG) announced today that the FDA has granted an EUA for its Cobas SARS-CoV-2 and Influenza A/B Test for use on Cobas 6800 and 8800 systems.
The test is also available in nations accepting the European Union’s CE Mark.
The new Roche test can provide simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in people.
“With the approaching flu season, this new test is particularly important as SARS-CoV-2 and influenza infections can hardly be differentiated by symptoms alone. Now, with a single test, healthcare professionals can confidently provide the right diagnosis and most effective treatment plan for their patients,” Roche Diagnostics CEO Thomas Schinecker said in a news release.